ATH-1017 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinson Disease Dementia
Conditions
Parkinson Disease Dementia, Dementia With Lewy Bodies
Trial Timeline
Jan 20, 2022 → Apr 19, 2023
NCT ID
NCT04831281About ATH-1017 + Placebo
ATH-1017 + Placebo is a phase 2 stage product being developed by LeonaBio for Parkinson Disease Dementia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04831281. Target conditions include Parkinson Disease Dementia, Dementia With Lewy Bodies.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04831281 | Phase 2 | Terminated |
| NCT04491006 | Phase 2 | Completed |
| NCT04488419 | Phase 2/3 | Completed |
Competing Products
20 competing products in Parkinson Disease Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| NAV5001 + DaTscan | Navidea Biopharmaceuticals | Phase 3 | 69 |
| exidavnemab + Placebo Comparator | BioArctic AB | Phase 2 | 49 |
| LY4006896 + Placebo | Eli Lilly | Phase 1 | 33 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 52 |
| Mirabegron + Placebo | Astellas Pharma | Approved | 85 |
| E2007 | Eisai | Phase 3 | 77 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Phase 3 | 77 |
| GPI 1485 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | 77 |
| Equfina 50 mg | Eisai | Pre-clinical | 23 |
| Equfina | Eisai | Pre-clinical | 23 |
| perampanel + placebo | Eisai | Phase 2 | 52 |
| Lemborexant + placebo | Eisai | Approved | 85 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | 77 |
| Safinamide Mesilate | Eisai | Approved | 85 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |